Evidence map›Paper›PMID 33398524›Full record

ArticleAmino acids2021

Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan.

Declan M Gorman, John Lee, Colton D Payne, Trent M Woodruff, Richard J Clark

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Amino acids, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Declan M GormanSchool of Biomedical Sciences, The University of Queensland, Brisbane, Australia.ORCID https://orcid.org/0000-0003-4933-3271
John LeeSchool of Biomedical Sciences, The University of Queensland, Brisbane, Australia.ORCID https://orcid.org/0000-0002-9976-7396
Colton D PayneSchool of Biomedical Sciences, The University of Queensland, Brisbane, Australia.ORCID https://orcid.org/0000-0002-9316-1465
Trent M WoodruffSchool of Biomedical Sciences, The University of Queensland, Brisbane, Australia.ORCID https://orcid.org/0000-0003-1382-911X
Richard J ClarkSchool of Biomedical Sciences, The University of Queensland, Brisbane, Australia. richard.clark@uq.edu.au.ORCID http://orcid.org/0000-0002-6807-5426
The University of Queensland · AU

Funding

National Health and Medical Research Council APP8881111
6 · The paper itself

Abstract

The complement component C5 inhibitory peptide zilucoplan is currently in phase III clinical trials for myasthenia gravis (MG). Despite being at an advanced stage of clinical development, there have been no published reports in the literature detailing its chemical synthesis. In this work, we describe an approach for the chemical synthesis of zilucoplan and validate that the synthesised compound blocks LPS-induced C5a production from human blood.

Indexed as

Complement C5Complement Inactivating AgentsHumansInhibitory Concentration 50LipopolysaccharidesMolecular StructurePeptides, CyclicSolid-Phase Synthesis TechniquesComplement C5Complement Inactivating AgentsLipopolysaccharidesPeptides, CycliczilucoplanC5C5aComplementPeptidesPeptide synthesisRA101495Zilucoplan

Identifiers

PMID33398524
PMCPMC7781173
OpenAlexW3119145102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.